Last reviewed · How we verify

AB-106 — Competitive Intelligence Brief

AB-106 (AB-106) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TGF-β receptor inhibitor. Area: Oncology.

phase 2 TGF-β receptor inhibitor TGF-β receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

AB-106 (AB-106) — Nuvation Bio Inc.. AB-106 is a TGF-β receptor inhibitor that blocks transforming growth factor-beta signaling to modulate immune responses and reduce fibrosis.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
AB-106 TARGET AB-106 Nuvation Bio Inc. phase 2 TGF-β receptor inhibitor TGF-β receptor
Pirfenidone Oral Product Pirfenidone Oral Product Capital Medical University phase 3 Antifibrotic TGF-β receptor
TAS6417 TAS6417 Taiho Oncology, Inc. phase 3 TGF-β receptor inhibitor ALK5 (activin receptor-like kinase 5)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TGF-β receptor inhibitor class)

  1. Nuvation Bio Inc. · 1 drug in this class
  2. Ocuphire Pharma, Inc. · 1 drug in this class
  3. Taiho Oncology, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AB-106 — Competitive Intelligence Brief. https://druglandscape.com/ci/ab-106. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: